Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections |
| |
Authors: | Steenbergen Judith N Alder Jeff Thorne Grace M Tally Francis P |
| |
Affiliation: | Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA. Judith.steenbergen@cubist.com |
| |
Abstract: | Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|